関連する実験動画
Updated: Feb 12, 2026

05:14
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
5.4K
ラミノパチー性拡張型心筋症におけるテロメア短縮
Alex C Y Chang1,2,3, Gaspard Pardon4,5, Andrew C H Chang4,5
1Department of Cardiology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. alexchang@shsmu.edu.cn.
NPJ Regenerative medicine
|February 10, 2026
まとめ
LMNA遺伝子変異によって引き起こされるラミノパチーは、心臓の問題や早期老化につながります。本研究は、LMNA変異が心筋細胞のテロメア短縮を引き起こし、ラミノパチーと老化を結びつけることを示しています。
科学分野:
- 心血管生物学
- 老化の遺伝学
- 希少疾患
背景:
- ラミノパチーはLMNA遺伝子の変異に起因する希少な遺伝性疾患です。
- LMNAは核構造と細胞の安定性に不可欠であり、筋肉、神経、心臓に影響を与えます。
- ラミノパチーと早期老化との間には関連がありますが、その根本的なメカニズムは不明です。
研究 の 目的:
- LMNA変異と心臓における老化表現型の関連を調べること。
- ラミノパチー関連心機能障害におけるテロメア長の役割を探求すること。
主な方法:
- ヒトのラミノパチー性心臓組織からの心筋細胞の分析。
- LMNA変異を有する患者由来のiPS細胞由来心筋細胞(hiPSC-CM)の利用。
- ラミノパチー性マウス心筋細胞モデルの採用。
主要な成果:
- ラミノパチー性心臓の心筋細胞ではテロメア短縮が観察されました。
- hiPSC-CMにおけるLMNA変異は、心筋の拡大と収縮能の低下を引き起こしました。
- ラミノパチー性マウスの心筋細胞ではテロメアの短縮が認められました。
結論:
- LMNA変異はテロメア短縮を介してラミノパチーにおける心機能障害に寄与します。
- 本研究は、ラミノパチーと老化プロセスとの間の細胞レベルでの関連性を示しています。
- テロメア短縮は、ラミノパチー性心筋症における重要な表現型です。
関連する概念動画
Cardiomyopathy II: Dilated Cardiomyopathy
589
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
589
Telomeres and Telomerase
27.4K
In eukaryotic DNA replication, a single-stranded DNA fragment remains at the end of a chromosome after the removal of the final primer. This section of DNA cannot be replicated in the same manner as the rest of the strand because there is no 3’ end to which the newly synthesized DNA can attach. This non-replicated fragment results in gradual loss of the chromosomal DNA during each cell duplication. Additionally, it can induce a DNA damage response by enzymes that recognize single-stranded...
27.4K
Telomeres and Telomerase
7.4K
7.4K
Cardiomyopathy III: Hypertrophic Cardiomyopathy
526
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
526
Cardiomyopathy IV: Restrictive Cardiomyopathy
587
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
587
Cardiomyopathy V: Interprofessional Care
470
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
470

